SAT0164 The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study

Abstract

BackgroundC-EARLY is a phase 3 study in DMARD-naïve patients (pts) with early active RA.ObjectivesTo assess efficacy and safety of certolizumab pegol (CZP)+MTX vs placebo (PBO)+MTX treatment in inducing and maintaining...